StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) company profile

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

About Galectin Therapeutics

Pharmaceutical Preparations, SIC 2834

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies for fibrotic conditions and cancers. The company utilizes plant-derived complex carbohydrates to create compounds that inhibit galectin proteins, particularly galectin-3. Its lead drug candidate is belapectin, which is evaluated for treating metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, as well as head and neck cancers. Additionally, the company develops orally administered small-molecule inhibitors through a joint venture subsidiary. Because all drug candidates remain in clinical or preclinical development, the firm has no commercial customers and directs its therapies toward patients suffering from chronic liver disease and life-threatening malignancies.

The company is headquartered in Norcross, Georgia, near Atlanta, and maintains a laboratory facility in the Boston, Massachusetts area. Its clinical trial footprint includes more than 150 study sites established across 14 countries, with operations and patient enrollment spanning the United States, Europe, and Latin America.

Summary of the business section of Galectin Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Galectin Therapeutics Inc
Founded
2000
Headquarters
Norcross, GA
Address
4960 Peachtree Industrial Boulevard, Suite 240 30071
Phone
(678) 620-3186
Employees
9, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Atlanta, Georgia

Stock & identifiers

Ticker
GALT
Exchange
Nasdaq
IPO date
Sep 4, 2002
Shares outstanding
101M, Aug 6, 2026
Public float
$109.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-6 reverse, Mar 23, 2012
SEC CIK
1133416
CUSIP
363225202
ISIN
US3632252025
FIGI
BBG000BK6FP5
Share class FIGI
BBG001S9NYW2
LEI
5299004HFYSAZM2ALW85
EIN
04-3562325

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joel LewisPresident and CEO, Director778,260
Khurram JamilChief Medical Officer16,250
Jack W. CallicuttChief Financial Officer7,614
Richard E. UihleinDirector52,523,297
Harold H. ShlevinDirector28,768
Henry BremDirector0
Kary EldredDirector70,107
Benjamin Carson SrDirector–
Gilbert F. AmelioDirector60,614
Gilbert S. OmennDirector66,769
Elissa J. SchwartzDirector1,000
Richard A. Zordani Jr.Director44,083
Kevin D. FreemanDirector137,269
Marc RubinDirector13,581

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.17M$1.69M$929.35K$322–
FY2024$1.19M$1.05M$831.40K$78–
FY2023$963.65K$1.06M$665.85K$147–
FY2022$974.18K$665.81K$680.57K$55–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Joel Lewis
Chief Executive Officer & President
$624.00K$312.00K$182.76K$56.02K$1.17M-1%
Khurram Jamil, M.D.
Chief Medical Officer
$500.00K$350.00K$130.55K$71.58K$1.05M+11%
Jack W. Callicutt
Chief Financial Officer
$400.00K$220.00K$130.55K$56.02K$806.56K+13%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had nine full-time employees, six of whom are involved primarily in management of our research and development and clinical trials and three who were involved primarily in management and administration of our Company.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?